(S)-(2-Methylpyrid-5-yl)-6-[(3-[18F]fluoro-2-hydroxy)propoxy]quinoline
([18F]SMBT-1) was recently developed as a novel class of
selective and reversible monoamine oxidase-B (MAO-B) tracers for in
vivo imaging of reactive astrogliosis via positron emission tomography.
To investigate the effect of the chirality of [18F]SMBT-1
on tracer performance, we synthesized (S)-[18F]6 ([18F]SMBT-1) and (R)-[18F]6 and compared their binding properties,
pharmacokinetics, and metabolism. (S)-6 showed higher binding affinity to MAO-B and lower binding affinity
to MAO-A than (R)-6, demonstrating a
higher selectivity ratio (MAO-B/MAO-A). A pharmacokinetic study in
mice demonstrated that both (S)-[18F]6 and (R)-[18F]6 showed
sufficient initial brain uptake. However, (S)-[18F]6 was cleared significantly faster from the
body. An abundant sulfoconjugate metabolite M2 was observed
in plasma for (S)-[18F]6 but
not for (R)-[18F]6. In vitro
sulfation assays confirmed that (S)-6 was more reactive than (R)-6, consistent
with the in vivo findings. Mefenamic acid, a selective sulfotransferase
1A1 (SULT1A1) inhibitor, strongly inhibited the in vitro sulfation
of (S)-6 by mouse liver fractions, human
liver cytosol fractions, and human recombinant SULT1A1 enzyme. Genetic
polymorphisms of SULT1A1 did not affect the sulfation of (S)-6 in vitro. In conclusion, (S)-[18F]6 had a more favorable binding affinity
and binding selectivity for MAO-B than (R)-[18F]6. Additionally, (S)-[18F]6 also possessed better pharmacological and
metabolic properties than (R)-[18F]6. These results suggest that (S)-[18F]6 ([18F]SMBT-1) is a promising candidate
for application in the imaging of MAO-B in vivo.